Discovers and develops novel therapeutic medicines, primarily in oncology and hematology. Manufactures its own pharmaceutical products for global distribution. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
Average growth of 46% a year over the last 4 years. Red columns mark years that ended in a loss.
If every debt were paid off today, $3.5B would still be left in the vault — a solid cushion for hard times.
The market pays 70.4× for every dollar this company earns in a year — a price that already assumes things go well.
Analysts' average target sits 40% above today's price.
The stock trades 54% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 46% a year on average.
There is $4.5B in the vault; even if every debt were paid off, $3.5B would remain.
The company’s market value is 70 times its annual profit. Even a small disappointment could hit the price hard.
Over the last 12 months, executives reported 189 sells against just 46 buys. Not an alarm bell by itself, but a number worth watching.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.